Download PDF
Digestive Disease Interventions 2022; 06(01): 037-040
DOI: 10.1055/s-0041-1742102
Review Article

Immune Response to Locoregional Therapy

Amanda R. Smolock
1   Division of Vascular and Interventional Radiology, Department of Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin
,
Sarah B. White
1   Division of Vascular and Interventional Radiology, Department of Radiology, Medical College of Wisconsin, Milwaukee, Wisconsin
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

The immune response to cancer is an ongoing area of interest and is the focus of newer systemic agents. Liver-directed therapy has been the standard treatment for primary and metastatic disease limited to the liver. It is increasingly being recognized that these therapies may influence a broader systemic response and immune activation. The clinical and translational data supporting this phenomenon are reviewed herein. The findings and potential impact of the immune response to liver-directed therapies are summarized in this article.

Keywords

liver-directed therapy - immune system - inflammatory response


Publication History

Received: 27 September 2021

Accepted: 24 November 2021

Article published online:
04 January 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Lu C, Rong D, Zhang B. et al. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities. Mol Cancer 2019; 18 (01) 130
    CrossrefPubMedGoogle Scholar
  • 2 Borst J, Ahrends T, Bąbała N, Melief CJM, Kastenmüller W. CD4+ T cell help in cancer immunology and immunotherapy. Nat Rev Immunol 2018; 18 (10) 635-647
    CrossrefPubMedGoogle Scholar
  • 3 Mizukoshi E, Yamashita T, Arai K. et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology 2013; 57 (04) 1448-1457
    CrossrefPubMedGoogle Scholar
  • 4 Liao Y, Wang B, Huang ZL. et al. Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma: a prospective study. PLoS One 2013; 8 (04) e60444
    CrossrefPubMedGoogle Scholar
  • 5 Ayaru L, Pereira SP, Alisa A. et al. Unmasking of α-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. J Immunol 2007; 178 (03) 1914-1922
    CrossrefPubMedGoogle Scholar
  • 6 Kohles N, Nagel D, Jüngst D, Stieber P, Holdenrieder S. Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy. Tumour Biol 2012; 33 (06) 2401-2409
    CrossrefPubMedGoogle Scholar
  • 7 Kim MJ, Jang JW, Oh BS. et al. Change in inflammatory cytokine profiles after transarterial chemotherapy in patients with hepatocellular carcinoma. Cytokine 2013; 64 (02) 516-522
    CrossrefPubMedGoogle Scholar
  • 8 Fan W, Zhang Y, Wang Y, Yao X, Yang J, Li J. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization. PLoS One 2015; 10 (03) e0119312
    CrossrefPubMedGoogle Scholar
  • 9 Huang ZL, Luo J, Chen MS, Li JQ, Shi M. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol 2011; 22 (05) 702-709
    CrossrefPubMedGoogle Scholar
  • 10 Sullivan KM, Groeschl RT, Turaga KK. et al. Neutrophil-to-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma: a Western perspective. J Surg Oncol 2014; 109 (02) 95-97
    CrossrefPubMedGoogle Scholar
  • 11 Tischfield D, Gurevich A, Johnson O. et al. Transarterial embolization modulates the immune response within target and non-target hepatocellular carcinomas. bioRxiv 2020; :2020.11.07.372896 DOI: 10.1101/2020.11.07.372896.
    CrossrefPubMedGoogle Scholar
  • 12 Avritscher R, Jo N, Polak U. et al. Hepatic arterial bland embolization increases Th17 cell infiltration in a syngeneic rat model of hepatocellular carcinoma. Cardiovasc Intervent Radiol 2020; 43 (02) 311-321
    CrossrefPubMedGoogle Scholar
  • 13 Gómez V, Mustapha R, Ng K, Ng T. Radiation therapy and the innate immune response: clinical implications for immunotherapy approaches. Br J Clin Pharmacol 2020; 86 (09) 1726-1735
    CrossrefPubMedGoogle Scholar
  • 14 Mole RH. Whole body irradiation; radiobiology or medicine?. Br J Radiol 1953; 26 (305) 234-241
    CrossrefPubMedGoogle Scholar
  • 15 Chew V, Lee YH, Pan L. et al. Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. Gut 2019; 68 (02) 335-346
    CrossrefPubMedGoogle Scholar
  • 16 Craciun L, de Wind R, Demetter P. et al. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy. BMC Cancer 2020; 20 (01) 135
    CrossrefPubMedGoogle Scholar
  • 17 Carr BI. Hepatic arterial 90yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 2004; 10 (2, Suppl 1): S107-S110
    CrossrefPubMedGoogle Scholar
  • 18 Salem R, Lewandowski RJ, Atassi B. et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16 (12) 1627-1639
    CrossrefPubMedGoogle Scholar
  • 19 Domouchtsidou A, Barsegian V, Mueller SP. et al. Impaired lymphocyte function in patients with hepatic malignancies after selective internal radiotherapy. Cancer Immunol Immunother 2018; 67 (05) 843-853
    CrossrefPubMedGoogle Scholar
  • 20 D'Emic N, Engelman A, Molitoris J. et al. Prognostic significance of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients treated with selective internal radiation therapy. J Gastrointest Oncol 2016; 7 (02) 269-277
    PubMedGoogle Scholar
  • 21 Zerbini A, Pilli M, Laccabue D. et al. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology 2010; 138 (05) 1931-1942
    CrossrefPubMedGoogle Scholar
  • 22 Hänsler J, Wissniowski TT, Schuppan D. et al. Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol 2006; 12 (23) 3716-3721
    CrossrefPubMedGoogle Scholar
  • 23 Erinjeri JP, Thomas CT, Samoilia A. et al. Image-guided thermal ablation of tumors increases the plasma level of interleukin-6 and interleukin-10. J Vasc Interv Radiol 2013; 24 (08) 1105-1112
    CrossrefPubMedGoogle Scholar
  • 24 Zerbini A, Pilli M, Fagnoni F. et al. Increased immunostimulatory activity conferred to antigen-presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation. J Immunother 2008; 31 (03) 271-282
    CrossrefPubMedGoogle Scholar
  • 25 Wisnowski TT, Hänsler J, Neureiter D. et al. Erratum: activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits (cancer research (October 1, 2003) (6496–6500)). Cancer Res 2003; 63 (21) 7543
    PubMedGoogle Scholar
  • 26 Dromi SA, Walsh MP, Herby S. et al. Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity. Radiology 2009; 251 (01) 58-66
    CrossrefPubMedGoogle Scholar
  • 27 Jansen MC, van Hillegersberg R, Schoots IG. et al. Cryoablation induces greater inflammatory and coagulative responses than radiofrequency ablation or laser induced thermotherapy in a rat liver model. Surgery 2010; 147 (05) 686-695
    CrossrefPubMedGoogle Scholar
  • 28 Zhang Z, Li W, Procissi D, Tyler P, Omary RA, Larson AC. Rapid dramatic alterations to the tumor microstructure in pancreatic cancer following irreversible electroporation ablation. Nanomedicine (Lond) 2014; 9 (08) 1181-1192
    CrossrefPubMedGoogle Scholar
  • 29 White SB, Zhang Z, Chen J, Gogineni VR, Larson AC. Early immunologic response of irreversible electroporation versus cryoablation in a rodent model of pancreatic cancer. J Vasc Interv Radiol 2018; 29 (12) 1764-1769
    CrossrefPubMedGoogle Scholar
  • 30 Yang J, Eresen A, Shangguan J, Ma Q, Yaghmai V, Zhang Z. Irreversible electroporation ablation overcomes tumor-associated immunosuppression to improve the efficacy of DC vaccination in a mice model of pancreatic cancer. OncoImmunology 2021; 10 (01) 1875638
    CrossrefPubMedGoogle Scholar